FDA Authorized Johnson & Johnson Robotic Surgery System
The regulatory approval of the OTTAVA system for general surgery coincides with a positive outlook for the company's annual sales.
Updated on Oct. 13, 2026 in Healthcare
Live Poll
Do you believe major medical technology innovations generally lead to better patient outcomes in your area?
In July 2026, the FDA granted de novo authorization to Johnson & Johnson for its OTTAVA robotic surgery system. This platform is now approved for 10 general surgery procedures, including hiatal hernia repair and gastric bypass.
Why it matters
The authorization of this table-integrated system marks a significant expansion of the company's surgical capabilities. By integrating with the Polyphonic digital ecosystem, the device aims to provide clinicians with new data-driven insights during procedures.
Johnson & Johnson reported $25.4 billion in sales for the third quarter of 2026, reflecting a 5.9% growth rate. The company now forecasts full-year 2026 operational sales growth between 6.7% and 7.1%.
The players
Johnson & Johnson
This multinational corporation develops medical devices, pharmaceuticals, and consumer packaged goods.
Food and Drug Administration
This federal agency is responsible for protecting public health by ensuring the safety and efficacy of medical devices and human drugs.
The details
The OTTAVA system utilizes a table-integrated design specifically engineered for soft tissue robotic surgery. The unit functions within the broader Polyphonic digital ecosystem to capture and analyze procedure data in real time.
Timeline
July 2026: FDA granted de novo authorization to the OTTAVA system.
July 29, 2026: The company previously issued guidance for sales growth.
Q3 2026: Reported quarterly sales reached $25.4 billion.
Full-year 2026: The company expects to exceed $100 billion in annual revenue.
Market Landscape
The introduction of the OTTAVA system deepens Johnson & Johnson's vertical integration by tying hardware sales to its proprietary digital service platform. This strategy positions the company to compete more effectively against established incumbents in the surgical robotics sector.
The expansion of robotic surgery options may eventually influence the availability and technical standards of common procedures like hiatal hernia repair in hospitals. While the immediate financial impact on patients depends on insurance coverage and facility adoption, the system is designed to streamline clinical data collection during surgery.
The takeaway
The approval of the OTTAVA system reflects a broader push by medical device manufacturers to capture data through digital ecosystems. Healthcare providers and patients can expect increased integration of automated surgical tools as companies look to drive long-term revenue growth.
Further reading
Find more updates on industry developments at Healthcare.
Live Poll
Do you believe major medical technology innovations generally lead to better patient outcomes in your area?
